The data suggest that study participants taking 800mg of Flurizan demonstrated a substantial benefit over other dose groups in the study and that this benefit continued to increase over 24 months, for each of the evaluated areas of cognition, memory loss, global function and activities of daily living.
The data also suggest that during the follow-on period from months 12 to 24, the benefit of Flurizan increases in terms of both effect size and significance, the longer patients remain on Flurizan.
According to the company, 94% of patients in this phase II study were receiving stable doses of acetylcholinesterase inhibitors, FDA-approved drugs for symptomatic treatment of Alzheimer’s disease, at the time of enrollment. Thus, the benefits of Flurizan observed in these patients were over and above the current standard of care.
“The 24 month data completes the phase II follow-on trial with mounting evidence of efficacy against mild Alzheimer’s disease that consistently increased over the course of the study,” said Dr Adrian Hobden, president of Myriad Pharmaceuticals. “The results are consistent with a mode of action for Flurizan that is modifying the course of the underlying disease process.”
Results from the study were presented at the International Conference on Alzheimer’s disease and Related Disorders, in Madrid, Spain, by Dr Gordon Wilcock, professor of clinical gerontology at the University of Oxford, and lead investigator for the phase II trial.